By Fineline Cube 
Gan & Lee Pharmaceuticals (SHA: 603087) announced today that it has transferred its controlling stake in its wholly‑owned subsidiary, Gangan Medical Technology Jiangsu Co., Ltd. (Gangan MedTech) to Hillhouse Investment. The move aligns with Gan & Lee’s strategy to consolidate its core pharmaceutical business while allowing Hillhouse to prop up MedTech’s global growth trajectory.
Transaction Highlights
- Ownership Transfer – Gan & Lee will retain a minority holding in MedTech; Hillhouse acquires 100 % of the remaining equity.
- Capital Deployment – Proceeds will fund strategic R&D in endocrine and metabolic therapeutics, bolstering Gan & Lee’s innovative drug pipeline.
- Operational Synergy – Hillhouse’s expertise in medical‑device operations will accelerate MedTech’s manufacturing scale‑up, R&D integration, and market expansion.
MedTech’s Value Proposition
- Specialization – Pioneering high‑quality drug delivery devices with FDA and EU CE MDR certification.
- Quality Framework – Robust international‑standard compliance and quality‑management system.
- Innovation Pipeline – Continuous product development aimed at addressing unmet needs in drug delivery.
Forward‑Looking Statements
This release contains forward‑looking statements regarding the transaction, potential future collaborations, and related market developments. These statements are based on current expectations and involve risks and uncertainties that could cause actual results to differ materially.-Fineline Info & Tech